Printer Friendly

Ocular Therapeutix Names Goldstein as Chief Medical Officer.

M2 PHARMA-September 11, 2017-Ocular Therapeutix Names Goldstein as Chief Medical Officer

(C)2017 M2 COMMUNICATIONS

- Bedford, Massachusetts-based ocular biopharmaceuticals specialist Ocular Therapeutix, Inc. (NASDAQ: OCUL) has appointed Michael Goldstein, M.D., M.B.A., as Chief Medical Officer (CMO), the company said.

Goldstein is an ophthalmologist, having held several senior medical leadership positions with ophthalmology-focused pharmaceutical companies and published extensively in multiple ophthalmology scientific journals.

In his roles CMO, Goldstein will oversee the clinical development of the company's product pipeline.

Prior to joining Ocular Therapeutix, Goldstein served as CMO of Applied Genetic Technologies Corp. (AGCT), a clinical-stage biotechnology company focused on the development of products for the treatment of rare diseases, with a focus on ophthalmology.

Before joining AGTC, he held several positions of increasing responsibility with Eleven Biotherapeutics, including CMO and vice president of clinical research.

Since 2002, Goldstein has served as co-director, cornea and external disease service and assistant professor of ophthalmology at the New England Eye Center and Tufts University School of Medicine.

Previously, he was director of Refractory Surgery Service and Assistant Professor of Ophthalmology at the University of Florida College of Medicine.

Ocular Therapeutix is focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, Dextenza (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 11, 2017
Words:254
Previous Article:Medivir announces discontinuation by Janssen R&D of JNJ-4178 development.
Next Article:NIAID, Zavante Partner in Clinical Trial of Zolyd as Bacterial Pneumonia Treatment.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters